Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.4552W HIGH $11.67
Volume
271.30 K
Value Traded
5.75 M
Short % Float
9.77%
Days to Cover
8.5
-5.57%Week
+1.23%1 Month
-3.15%3 Month
-34.05%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
239.49 M
EPS (TTM)
-4.45
P/E Ratio
-
Ent. Value
261.77 M
Total Shares
48.68 M
Float Shares
47.24 M
Insiders
2.95%
Institutions
75.53%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NUS Catalyst Timeline
Dated clinical, regulatory and corporate events for NuSkin Enterprises, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for NuSkin Enterprises, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
Past FDA Catalysts and PDUFA Decisions
How NUS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every NUS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Winett James MDirector | Sell | -7,203 37,448 held | $5.62 | 06/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NUS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NUS for Q2 2026. | ||||
NUS Institutional Ownership Trends
NUS Short Interest
Shares sold short, counted twice a month.
9.77%
Short % of Float
of tradable shares sold short
4.6M
Shares Sold Short
-3.2% vs prior count
8.5 High
Days to Cover
trading days of normal volume to buy every short share back
544.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NUS ranks across every disease it competes in
Competitive Position is a premium feature
See how NUS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNUS News
-NUS
Oct 22, 2026▲ +3.4%today
Nu Skin Enterprises to Announce Third Quarter 2026 Financial Results
Nu Skin Enterprises, Inc. will announce its third quarter 2026 financial results on November 5, after market close. The management team will hold a conference call at 5 p.m. ET to discuss these results and future business initiatives. Investors can access the webcast of the call.
Read more →-NUS
Sep 3, 2026Nu Skin Ranked the World’s #1 Company for Beauty and Wellness Device Systems for Third Consecutive Year
Nu Skin Enterprises Inc. has been recognized as the world's leading company in beauty and wellness device systems for the third consecutive year by Euromonitor International. This accolade reflects the company's commitment to innovation and its long-term vision in the wellness sector. CEO Ryan Napierski emphasized the importance of personalized and intelligent wellness solutions for the future.
Read more →-NUS
Aug 10, 2026▼ -5.4%on this news
Nu Skin Enterprises Reports Second Quarter Results
Nu Skin Enterprises reported a significant decline in its second quarter results for 2026, with revenues falling to $320.1 million, a decrease of 17.1% year-over-year. The company also reported a loss in earnings per share of $(5.14), which reflects non-cash impairments and tax charges. Additionally, the customer base and paid affiliates both saw notable reductions, indicating challenges in maintaining growth.
Read more →-NUS
Aug 10, 2026▼ -5.4%on this newsshared move
Nu Skin Enterprises Announces Quarterly Dividend
Nu Skin Enterprises has announced a quarterly cash dividend of $0.06 per share. This dividend will be paid on September 9, 2026, to shareholders of record as of August 28, 2026. The announcement reflects the company's ongoing commitment to returning value to its shareholders.
Read more →-NUS
Jul 21, 2026Nu Skin Enterprises to Announce Second Quarter 2026 Financial Results
Nu Skin Enterprises, Inc. will announce its second quarter 2026 financial results on August 10 after market close. Following the release, the management team will hold a conference call at 5 p.m. ET to discuss the results and future business initiatives. A webcast of the call will be available for investors.
Read more →-NUS
May 15, 2026Nu Skin Reaches 900 Million Meals Purchased and Donated in its Global Fight for Child Nutrition
Nu Skin has reached a remarkable milestone by purchasing and donating 900 million meals as part of its global initiative to combat child nutrition issues. This achievement underscores the company's dedication to addressing hunger and improving the lives of children worldwide. The initiative showcases Nu Skin's commitment to social responsibility and community support.
Read more →-NUS
May 7, 2026Nu Skin Enterprises Reports First Quarter Results
Nu Skin Enterprises has reported its first quarter results, but the details of the financial performance are not provided in the article. The report appears to be brief and lacks specific insights into revenue, profit, or other key metrics. Further information may be necessary to assess the company's performance accurately.
Read more →-NUS
Apr 13, 2026Nu Skin Enterprises to Announce First Quarter 2026 Financial Results
Nu Skin Enterprises is set to announce its financial results for the first quarter of 2026. The announcement is anticipated by stakeholders as it will provide insights into the company's performance. Specific details regarding the results have not been disclosed yet.
Read more →-NUS
Apr 2, 2026Nu Skin Launches Prysm iO™: A Revolutionary AI-Powered Platform for Personalized Nutritional Wellness
Nu Skin Enterprises has launched Prysm iO, an AI-driven nutritional wellness platform. This device measures skin carotenoid levels in just 15 seconds, providing users with personalized insights into their antioxidant status. The platform is based on over 20 years of research and is designed to empower consumers to make informed health decisions.
Read more →-NUS
Mar 20, 2026Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer
Nu Skin Enterprises has appointed Chelsea Lantz as interim Chief Financial Officer following the resignation of James Thomas. Lantz, who has been with the company since 2011 and served as corporate controller since 2023, will guide the company's financial strategies. The board has also initiated a search for a permanent CFO. CEO Ryan Napierski highlighted Lantz's track record in enhancing operational performance and cost efficiency within the organization.
Read more →-NUS
Mar 9, 2026Nu Skin Appoints Chayce Clark as COO Clark to expand on his responsibilities as chief legal officer to oversee
Nu Skin Enterprises Inc. has appointed Chayce Clark as Chief Operating Officer, effective immediately. In this expansion of his role, Clark will combine his responsibilities as Chief Legal Officer with managing the company's operational functions and revenue performance. The move is part of Nu Skin's strategy to enhance global alignment and execution across its nearly 50 markets. As the company introduces its Prysm iO intelligent wellness platform and enters emerging markets like India, Clark's leadership is aimed at maximizing growth opportunities.
Read more →-NUS
Feb 12, 2026Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results Company provides initial outlook for Q1 and fiscal year 2026, forecasting a return to revenue growth by year's end
Nu Skin Enterprises (NUS) reported its fourth quarter and full year 2025 financial results, achieving earnings growth of over 50% but facing a revenue decline. The company anticipates a return to revenue growth by the end of 2026, driven by the launch of their new Prysm iO intelligent wellness platform. Despite a significant drop in customer numbers and projected revenue for Q1 2026 reflecting continued challenges, management expresses optimism about long-term growth opportunities, particularly with their market expansion initiatives in India.
Read more →-NUS
Nov 6, 2025Nu Skin Enterprises Reports Third Quarter Earnings
Nu Skin Enterprises reported its third quarter earnings for 2025, showing revenue of $364.2 million and an increased earnings per share of $0.34. The company is preparing for the limited introduction of its Prysm iO intelligent wellness platform and the pre-market opening in India. Despite strong growth in the Latin American region, overall customer numbers and paid affiliates have decreased. Nu Skin management remains optimistic about upcoming growth initiatives expected to enhance shareholder value.
Read more →-NUS
Aug 7, 2025Nu Skin Enterprises Reports Second Quarter Revenue at High End of Guidance and Earnings Per Share Above Guidance Company generates strong operating margin and cash position; narrows revenue and raises EPS guidance
Nu Skin Enterprises reported its second quarter earnings, with revenue at the high end of guidance and earnings per share exceeding projections. The company achieved an operating margin of 8% despite challenges in customer and affiliate numbers. Future growth prospects include the introduction of the Prysm iO intelligent wellness device and market expansion into India. Management has narrowed its revenue outlook and raised EPS guidance for 2025, reflecting improved financial performance and a stronger balance sheet.
Read more →-NUS
May 8, 2025▲ +7.1%on this news· ran to +29% by day 3
Nu Skin Enterprises Reports First Quarter Revenue at High End of Guidance
Nu Skin Enterprises announced its first quarter revenue for 2025, reporting $364.5 million, which falls at the high end of its guidance range. The company exceeded expectations for adjusted earnings but faced a year-over-year revenue decline of 12.7%. Despite some optimism highlighted by improvement in operating margins and plans for market expansion into India, challenges persist due to decreasing customer numbers and external economic factors impacting the business. Management remains focused on executing cost efficiency initiatives and maintaining shareholder value.
Read more →-NUS
Feb 13, 2025Nu Skin Enterprises Reports Fourth Quarter and Full-year 2024 Results Above Company Revenue Guidance
Nu Skin Enterprises announced better-than-expected fourth-quarter results for 2024, generating revenue above its guidance. Despite this, the company reported a significant year-over-year revenue decline of 12.0% and decreased customer engagement metrics. Looking forward, Nu Skin provided an initial outlook for Q1 and FY 2025, expecting gradual improvements in business trends but highlighting ongoing challenges in certain markets. Key initiatives include the launch of an innovative wellness product, Prysm iO, and the integration of the recently acquired Mavely.
Read more →-NUS
Jan 3, 2025▲ +14.8%on this news
Nu Skin Enterprises Announces Strategic Transaction of Mavely for $250 Million
Nu Skin Enterprises announced the strategic sale of its Mavely affiliate marketing technology platform to Later for approximately $250 million. This transaction will provide Nu Skin with capital for innovation and fortify its balance sheet, enabling stock buybacks under its existing program. The deal is expected to enhance the capabilities of both companies as they pursue a broader beauty and wellness ecosystem. This action also reflects a significant return on Nu Skin's earlier investment in Mavely.
Read more →-NUS
Nov 7, 2024Nu Skin Enterprises Reports Third Quarter Results
Nu Skin Enterprises (NYSE: NUS) reported its third quarter results, showing a revenue of $430.1 million, marking a decline of 13.8% compared to the previous year. The company noted that its performance was aligned with prior guidance, despite facing macroeconomic pressures. Additionally, Nu Skin's Rhyz segment demonstrated strong growth, helping to partially offset challenges in its core business. For the upcoming quarters, the company has adjusted its revenue and EPS outlook to reflect ongoing business challenges, projecting 2024 revenue between $1.70 billion and $1.73 billion.
Read more →About NuSkin Enterprises, Inc.
Headquarters75 WEST CENTER ST, PROVO, UT, 84601
BIOPHARMAWATCH ELITE PLUS
Trade the next NUS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime